studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 431A
dictors of RFS in overall patients include cirrhosis (hazard ratio
(HR)=2.337, p=0.006) and AFP level >20 ng/mL (HR=1.896,
p=0.026). The median RFS in NUC secondary prevention failure
and tertiary prevention groups were 54 and 36 months,
respectively (p=0.467). The 1-, 2- and 5-year RFS rates were
85.3%, 72.7%, 46.1% in the NUC secondary prevention failure
group, and 76.4%, 61.3%, 46.6% in tertiary prevention
group, respectively. Baseline viral loads, HBsAg levels and
virological response were not associated with RFS. In the subgroup
patients without cirrhosis, NUC secondary prevention
failure group had a trend of better RFS (p=0.057), whereas
the RFS was comparable between the two group in patients
with cirrhosis. Conclusions Continue NUC treatment has the
potential to reduce the risk of HCC recurrence in non-cirrhotic
patients despite secondary prevention had failed. Closely monitoring
is recommended for HBV-HCC patients with cirrhosis
after curative surgical resection even under NUC treatment.
Disclosures:
The following authors have nothing to disclose: I-Cheng Lee, Yi-Hsiang Huang,
Gar-Yang Chau, Teh-Ia Huo, Chien-Wei Su, Han-Chieh Lin
440
A Pilot Safety Study of Nature Killer Cells From Sibship
to Treat the Recurrence of Hepatocellular Carcinoma
After Liver Transplantation
Guo-Ying Wang, Yang Yang, Gui-Hua Chen; Liver Transplantation
Center, the Third Affiliated Hospital, Sun Yat-sen University, Organ
Transplantation Research Institute, Guangzhou, China
Objective: Nature Killer (NK) Cells have been thought to play
a pivotal role in innate immunity. However, the safety and efficacy
of NK cells for the treatment of hepatocellular carcinoma
(HCC) recurrence after liver transplantation (LT) is unknown. In
this study, we investigated whether the injection of activated
NK cells (CD3 - CD56 + cells) from the sibship with the same
blood type is safe for the treatment of HCC recurrence after LT.
Methods: Six patients with HCC recurrence after LT were eligible
and enrolled in this study. The patients received injections
of 5 × 10 9 NK cells from the sibship with the same blood type
4 times at a frequency of once every two weeks. Lymphocytes
were extracted from the peripheral blood mononuclear cells
and cultured with IL-2 and other cytokines for 2 weeks. The
purity of lymphocytes was assessed by flow cytometric analysis,
and only the CD3 - CD56 + cells greater than 70% were
used. The adverse effects, laboratory tests, overall survival
were assessed. Results: No serious adverse effects, laboratory
abnormalities were identified as related to the treatment of
NK cells. Fix patients were alive in the follow-up period of 26
months while one died of liver failure due to tumor progression
after 2 months of NK cells infusion. There was no graft-versushost
disease in all 6 patients during follow-up. Conclusion:
In conclusion, we have demonstrated for the first time to our
knowledge that NK cells from sibship with the same blood type
can be used safely as adoptive immunotherapy for the treatment
of HCC recurrence after liver transplantation.
Disclosures:
The following authors have nothing to disclose: Guo-Ying Wang, Yang Yang,
Gui-Hua Chen
441
Serological markers of extracelllular matrix remodelling
for the diagnosis of HCC and the evaluation of tumour
pathogenesis
Roslyn Vongsuvanh 1 , Jacob George 1 , David van der Poorten 1 ,
Morten A. Karsdal 2 , Diana J. Leeming 2 ; 1 Storr Liver Unit, Westmead
Millenium Institute, Westmead Hospital, Westmead, NSW,
Australia; 2 Nordic Bioscience, Fibrosis Biology and Biomarkers,
Herlev, Denmark
Liver fibrosis is associated with HCC, however, whether markers
of matrix turnover may be exploited for HCC evaluation,
remains poorly understood. Fragments of the extracellular
matrix (ECM) are released systemically during the process of
hepatic fibrosis. In this study, we assessed protein fingerprint
markers of the ECM in serum of patients with HCC compared
to cirrhosis, chronic liver disease and healthy controls. We
determined the diagnostic performance of these markers for
HCC in order to gain insight into the mechanisms linking matrix
turnover to HCC diagnosis. Methods Plasma from 86 HCC
patients, age and sex-matched to 86 cirrhotics, 86 hepatitis B
(HBV) non-cirrhotics and 86 healthy controls, were collected in
a cross-sectional study. ECM markers of matrix metaloproteinases
(MMP)-2, 7 or -9, derived collagen turnover of type I, III,
IV, VI (C1M, C3M, C4M2, C6M) and elastin (ELM7), as well
as formation of type III and IV collagen (Pro-C3, P4NP 7S) were
measured by ELISA. Results Mean plasma Pro-C3 levels were
significantly higher in HCC (33.12 ng/ml) than in cirrhotics
(22.2 ng/ml), HBV non-cirrhotics (12.18 ng/ml) and healthy
controls (9.03 ng/ml) (p